ERDERA scientific coordinator Daria Julkowska highlights goals for rare disease research in Europe

In a recent interview with Science Business, ERDERA Scientific Coordinator Daria Julkowska discussed the upcoming launch of the European Rare Diseases Research Alliance (ERDERA), its mission, and its critical role in advancing rare disease research across Europe.

This partnership, funded under Horizon Europe, is set to revolutionize the field of rare diseases with a seven-year budget of €380 million.

The partnership will launch its first funding calls in December 2024, as part of its mission to improve rare disease prevention, diagnosis, and treatment. Julkowska emphasized the need for a collaborative European approach, explaining, “For many rare diseases, the number of patients in any one country is often too small to support significance research. Therefore, strong collaboration is essential.”

ERDERA aims to accelerate diagnostic times, develop treatments, and improve the quality of life for Europe’s 30 million rare disease patients. It builds on more than 20 years of EU efforts in rare disease research, including the European Joint Programme on Rare Diseases (EJP RD).

Read the full interview on Science Business here.

This article is part of ERDERA’s ongoing efforts to communicate and engage with stakeholders across Europe and beyond, ensuring the success of this vital initiative.

News & Updates

You might also be interested in

November 2 @ 1:00 pm - 2:00 pm
ERDERA Ethics & Regulatory Webinar Series
November 25 - November 26
Discover practical pathways to repurpose medicines for rare diseases, exchange experiences and best practices between underrepresented and high-performing countries, and build new partnerships at the ERDERA Knowledge Exchange Meeting in Riga on 25-26 November.
ERDERA contributed to the first Journée nationale FrBioNet, bringing a European rare disease perspective to discussions with the French biobanking community.
ERDERA will return to the World Orphan Drug Congress Europe with a booth and an interactive pre-conference workshop examining where artificial intelligence can support rare disease research and therapeutic development, and where human expertise remains essential.